RVXCF (Resverlogix) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix ROE % Adjusted to Book Value?

Resverlogix's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Resverlogix's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Resverlogix's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Resverlogix ROE % Adjusted to Book Value Historical Data

The historical data trend for Resverlogix's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix ROE % Adjusted to Book Value Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Negative Equity

Resverlogix Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	Negative Equity	-	-

Competitive Comparison of Resverlogix's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Resverlogix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resverlogix's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Resverlogix's ROE % Adjusted to Book Value falls into.

Resverlogix ROE % Adjusted to Book Value Calculation

Resverlogix's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Resverlogix's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Resverlogix ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Resverlogix's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

0VF9:UK RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.